Clinical significance of sIL-2R levels in B-cell lymphomas

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Yoshida, Noriaki ^a,b,c   Oda, Miyo ^a   Kuroda, Yoshiaki ^a   Katayama, Yuta ^d   Okikawa, Yoshiko ^e   Masunari, Taro ^f   Fujiwara, Megumu ^d   Nishisaka, Takashi ^g   Sasaki, Naomi ^h   Sadahira, Yoshito ⁱ   Mihara, Keichiro ^a   Asaoku, Hideki ^d   Matsui, Hirotaka ^a   Seto, Masao ^b,c   Kimura, Akiro ^a,h   Arihiro, Koji ^a   Sakai, Akira ^a,j  

^a HIROSHIMA UNIVERSITY   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

^f CHUGOKU CENTRAL HOSPITAL   (Japan)

^g Hiroshima Prefecture Hiroshima Hospital   (Japan)

^h Kure Kyosai Hospital   (Japan)

ⁱ KAWASAKI MEDICAL SCHOOL   (Japan)

^j FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOMA, B-CELL; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-2; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84893598460     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078730     Document Type: Article

References (38)

1. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, et al. (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172-3177. (Pubitemid 16250575)
2. Murakami S (2004) Soluble interleukin-2 receptor in cancer. Front Biosci 9: 3085-3090.
3. Yasuda N, Lai PK, Ip SH, Kung PC, Hinuma Y, et al. (1988) Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 71: 1021-1026.
4. Rubin LA, Galli F, Greene WC, Nelson DL, Jay G (1990) The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine 2: 330-336.
5. Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y, et al. (1994) Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 73: 2753-2758. (Pubitemid 24166262)
6. Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, et al. (2012) Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol 30: 1635-1640.
7. Shipp MA (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329: 987-994.
8. Arcaini L, Merli M, Passamonti F, Rizzi S, Ferretti V, et al. (2010) Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol 149: 455-457.
9. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, et al. (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27: 4555-4562.
10. Federico M, Molica S, Bellei M, Luminari S (2009) Prognostic factors in low-grade non-Hodgkin lymphomas. Curr Hematol Malig Rep 4: 202-210.
11. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, et al. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109: 1857-1861. (Pubitemid 46348180)
12. Ambrosetti A, Nadali G, Vinante F, Ricetti MM, Todeschini G, et al. (1993) Soluble interleukin-2 receptor in hairy-cell leukemia: a reliable marker of disease. Int J Clin Lab Res 23: 34-37.
13. Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, et al. (2009) Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 20: 526-533.
14. Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, et al. (2005) Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 131: 73-79. (Pubitemid 40192931)
15. Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, et al. (2012) Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol 91: 705-714.
16. De Paiva CS, Yoon KC, Pangelinan SB, Pham S, Puthenparambil LM, et al. (2009) Cleavage of functional IL-2 receptor alpha chain (CD25) from murine corneal and conjunctival epithelia by MMP-9. J Inflamm (Lond) 6: 31.
17. El Houda Agueznay N, Badoual C, Hans S, Gey A, Vingert B, et al. (2007) Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships. Clin Exp Immunol 150: 114-123. (Pubitemid 47383297)
18. Ahn GO, Brown JM (2008) Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13: 193-205.
19. Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114: 623-633. (Pubitemid 39578752)
20. Liu D, Guo H, Li Y, Xu X, Yang K, et al. (2012) Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One 7: e31251.
21. Hayashibara T, Yamada Y, Onimaru Y, Tsutsumi C, Nakayama S, et al. (2002) Matrix metalloproteinase-9 and vascular endothelial growth factor: a possible link in adult T-cell leukaemia cell invasion. Br J Haematol 116: 94-102. (Pubitemid 34122065)
22. Mori N, Sato H, Hayashibara T, Senba M, Hayashi T, et al. (2002) Human T-cell leukemia virus type I Tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness. Blood 99: 1341-1349. (Pubitemid 34547090)
23. Lenz G, Wright G, Dave SS, Xiao W, Powell J, et al. (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359: 2313-2323.
24. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, et al. (2008) High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 26: 440-446. (Pubitemid 351171697)
25. Morito T, Fujihara M, Asaoku H, Tari A, Sato Y, et al. (2009) Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma. Cancer Sci 100: 1255-1260.
26. Popovic M, Sarin PS, Robert-Gurroff M, Kalyanaraman VS, Mann D, et al. (1983) Isolation and transmission of human retrovirus (human t-cell leukemia virus). Science 219: 856-859. (Pubitemid 13194772)
27. Borregaard N (2010) Neutrophils, from marrow to microbes. Immunity 33: 657-670.
28. Kang T, Yi J, Guo A, Wang X, Overall CM, et al. (2001) Subcellular distribution and cytokine- and chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in neutrophils. J Biol Chem 276: 21960-21968.
29. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555. (Pubitemid 35223554)
30. Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, et al. (2010) Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 60: 278-283.
31. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, et al. (2012) Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 120: 3280-3287.
32. Barros MH, Hassan R, Niedobitek G (2012) Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact. Clin Cancer Res 18: 3762-3771.
33. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78.
34. Solinas G, Schiarea S, Liguori M, Fabbri M, Pesce S, et al. (2010) Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol 185: 642-652.
35. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67.
36. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947.
37. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, et al. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282. (Pubitemid 38029949)
38. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, et al. (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105: 13520-13525.